Actinogen Medical Plans New Share Issue Amid Xanamem Progress
Company Announcements

Actinogen Medical Plans New Share Issue Amid Xanamem Progress

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical Limited is set to issue new shares and options following approval at their upcoming General Meeting. The company is making strides in developing Xanamem, a novel therapy targeting neurological diseases like Alzheimer’s and depression by controlling brain cortisol levels. Early clinical trials have shown promising results, generating interest among investors in the biotech sector.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Highlights Alzheimer’s Research Progress
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Advances Alzheimer’s Trials and Boosts Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App